金石亚药(300434) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 419,787,729.70, representing a 33.27% increase compared to CNY 314,985,330.83 in the same period last year[4]. - Net profit attributable to shareholders for Q1 2023 was CNY 143,460,482.45, a significant increase of 115.49% from CNY 66,575,529.07 in the previous year[4]. - The net profit after deducting non-recurring gains and losses was CNY 139,339,589.63, up 120.19% from CNY 63,281,312.18 year-on-year[4]. - The basic earnings per share for Q1 2023 was CNY 0.3571, reflecting a 110.06% increase from CNY 0.17 in the same quarter last year[4]. - Total operating revenue for Q1 2023 reached CNY 419,787,729.70, a significant increase from CNY 314,985,330.83 in the same period last year, representing a growth of approximately 33.3%[15]. - The company reported an operating profit of CNY 184,249,348.46, compared to CNY 80,200,301.74 in the previous year, reflecting an increase of approximately 129.1%[15]. - The total comprehensive income for Q1 2023 was CNY 142.50 million, compared to CNY 65.60 million in Q1 2022, reflecting an increase of 117.5%[16]. Assets and Liabilities - The company's total assets at the end of Q1 2023 were CNY 3,040,493,261.49, a slight decrease of 0.63% from CNY 3,059,913,477.69 at the end of the previous year[4]. - The total current assets at the end of the reporting period were CNY 1,245,227,814.53, a slight decrease from CNY 1,261,062,751.33 at the beginning of the year, down by approximately 1.3%[12]. - The total liabilities decreased to CNY 594,640,857.64 from CNY 756,559,066.03, a reduction of about 21.4%[13]. - The total equity attributable to shareholders increased to CNY 2,417,690,284.28 from CNY 2,274,229,801.83, reflecting a growth of approximately 6.3%[13]. - The cash and cash equivalents decreased to CNY 386,869,329.36 from CNY 440,308,115.39, a decline of about 12.1%[12]. - Inventory levels rose to CNY 216,145,442.93 from CNY 197,369,370.03, an increase of approximately 9.5%[12]. Cash Flow - The net cash flow from operating activities for Q1 2023 was negative CNY 57,691,400.00, a decline of 475.91% compared to a positive cash flow of CNY 15,346,997.87 in the same period last year[4]. - Cash inflows from operating activities totaled CNY 360.72 million, compared to CNY 264.45 million in Q1 2022, indicating a rise of 36.4%[19]. - The total cash outflow from investing activities was CNY 4.65 million, compared to CNY 45.71 million in Q1 2022, showing a decrease of 89.8%[19]. - The net cash flow from financing activities was CNY 7.37 million, with no cash inflow reported in Q1 2022[20]. Market and Operational Performance - The company experienced a significant increase in market demand for its main products, leading to improved operational performance[7]. - The company has implemented production mechanism adjustments and optimized production processes to significantly increase output in response to market demand[7]. - Research and development expenses increased to CNY 17,587,226.51 from CNY 12,937,760.46, marking a rise of about 36.3%[15]. Foreign Exchange and Non-Recurring Items - The company reported non-recurring gains totaling CNY 4,120,892.82 for the quarter, after accounting for tax effects[5]. - The company experienced a foreign exchange loss of CNY -272,954.05 in Q1 2023, compared to a loss of CNY -48,275.32 in Q1 2022[20].